Trial Profile
Prospective Randomized Multicenter Study in First-Line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms MAINTAIN; StiL NHL7
- 17 May 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2030.
- 17 May 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2030.
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology